Associated Papers
Differential metabolism of citalopram by 21 CYP3A4 variants: An in vitro experiment.
Wang P et al.
Journal of Psychopharmacology (oxford, England), 2025
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored.
Mwaniki RM et al.
Journal of Molecular Biology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.
Wang CC et al.
Biomedical Chromatography : Bmc, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population.
Hu X et al.
Peerj, 2024
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.
Zhang X et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions.
Kong Q et al.
Frontiers in Pharmacology, 2022
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Crystal Structures of Drug-Metabolizing CYPs.
Estrada DF et al.
Methods in Molecular Biology (clifton, N.j.), 2021
Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B et al.
Chemical Research in Toxicology, 2020
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF et al.
Drug Design, Development and Therapy, 2020
Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.
Li YH et al.
Basic & Clinical Pharmacology & Toxicology, 2019
Genetic analysis of pharmacogenomic VIP variants in the Blang population from Yunnan Province of China.
Zhang C et al.
Molecular Genetics & Genomic Medicine, 2019
Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes.
Numanagić I et al.
Nature Communications, 2018
Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro.
Fang P et al.
Drug Design, Development and Therapy, 2017
Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China's Shaanxi province.
Jin T et al.
Environmental Toxicology and Pharmacology, 2016
Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.
Jin T et al.
Bmc Genetics, 2016
Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China.
Jin T et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2015
Genetic polymorphisms in very important pharmacogenomic (VIP) variants in the Tibetan population.
Jin TB et al.
Genetics and Molecular Research : Gmr, 2015
Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.
Wang L et al.
Bmc Genetics, 2015
Genetic polymorphism of pharmacogenomic VIP variants in the Deng people from the Himalayas in Southeast Tibet.
Shi X et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 2015
Functional gene variants of CYP3A4.
Werk AN et al.
Clinical Pharmacology and Therapeutics, 2014
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D et al.
Journal of Personalized Medicine, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential.
Liu D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants.
Peters EJ et al.
Pharmacogenomics, 2008
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.
Lee SJ et al.
Journal of Clinical Pharmacology, 2006
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response.
Johnson MM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2005
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C et al.
American Journal of Epidemiology, 2004
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
Lamba JK et al.
Pharmacogenetics, 2002